Brief: Adlai Nortye Announces Clinical Trial Notification Submission And Hrec Approval
03/08/2026 14:22
BRIEF-Adlai Nortye Announces Clinical Trial Notification Submission And Hrec Approval Aug 3 (Reuters) - Adlai Nortye Ltd ANL.O:
ADLAI NORTYE ANNOUNCES CLINICAL TRIAL NOTIFICATION SUBMISSION AND HREC APPROVAL FOR THE PHASE I CLINICAL TRIAL OF PAN-RAS(ON) INHIBITOR ADC AN4035 IN AUSTRALIA
ADLAI NORTYE - IN PROCESS OF IND SUBMISSIONS FOR AN4035 TO U.S. FDA AND CHINA NMPA
Source text: ID:nGNX4yXw9r
Further company coverage: ANL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adlai Nortye
See all newsAdvisory: Alerts wrongly tagged to Merck & Co withdrawn
Brief: Adlai Nortye Appoints Christopher Liu, Pharmd, As Head Of Investor Relations And Public Relations
Brief: Adlai Nortye Announces Clinical Trial Notification Submission And Hrec Approval
Brief: Adlai Nortye Files For Mixed Shelf Offering Of Up To $600 Million
U.S. STOCKS ON THE MOVE-Netflix, J.B. Hunt, Arxis